Donghua Zhang

This study is testing a new treatment plan for adults with a type of blood cancer called acute myeloid leukemia (AML) who are too old or frail for standard strong chemotherapy. The plan uses a drug called selinexor, aiming to reduce or avoid traditional chemotherapy drugs to see …

This early-stage study is testing a personalized cell therapy called CAR-T for adults with certain hard-to-treat blood cancers that have returned or not responded to standard treatments. Researchers will check if the treatment is safe, how it behaves in the body, and if it shows …

This study is testing a new two-step treatment for adults with acute myeloid leukemia (AML) that has returned or not responded to standard chemotherapy. First, patients receive an immune cell therapy (CLL1 CAR-T) designed to target their cancer cells. This is followed by a stem c…

This study is testing a new type of personalized immune cell therapy called BCMA-GPRC5D CAR-T for people with advanced multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if this therapy is safe and can help patien…

This study is testing a new cell-based treatment for adults with B-cell non-Hodgkin lymphoma that has come back or hasn't responded to standard therapies. The main goals are to see if the treatment is safe and to find the best dose. Researchers will track how patients do for up t…